Ricevi le ultime notizie sulle azioni Finch Therapeutics Gr con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di FNCH

Ultime notizie per

Finch Therapeutics Gr

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

FINCH THERAPEUTCS GRP INC by Finch Therapeutics Group, Inc.

Finch Therapeutics Group Inc

FINEOS Corp Holdings PLC Chess Depository Interest

Comments

Finch Therapeutics Gr Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO